Compare MOB & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOB | SPRO |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.8M | 71.6M |
| IPO Year | 2021 | 2017 |
| Metric | MOB | SPRO |
|---|---|---|
| Price | $5.87 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 125.2K | ★ 1.3M |
| Earning Date | 03-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $150.10 | $300.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $4.33 | $1.08 |
| 52 Week High | $11.01 | $3.08 |
| Indicator | MOB | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 35.20 |
| Support Level | $5.46 | $1.10 |
| Resistance Level | $6.74 | $1.29 |
| Average True Range (ATR) | 0.51 | 0.06 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 48.06 | 46.67 |
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.